BioCentury
ARTICLE | Company News

June 19 Company Quick Takes: Catalent takes over manufacturing site from BMS; plus Lynparza, Myriad, Amgen and more

June 19, 2019 10:19 PM UTC

Catalent buys Italian facility from BMS
Catalent Inc. (NYSE:CTLT) will buy an Italian manufacturing facility from Bristol-Myers Squibb Co. (NYSE:BMY) for an undisclosed amount. Catalent will manufacture oral solid, biologics and sterile products at the site, and will also continue to manufacture BMS's products. The deal is expected to close by year end.

Lynparza adds indication in Japan
Japan's Pharmaceuticals and Medical Devices Agency approved Lynparza from AstraZeneca plc (LSE:AZN; NYSE:AZN) and Merck & Co. Inc. (NYSE:MRK) as maintenance treatment after chemotherapy in patients with BRCA-mutated ovarian cancer. The PARP inhibitor -- the only one approved in Japan -- is also approved as maintenance treatment in women with platinum-sensitive, relapsed ovarian cancer regardless of BRCA mutation, and to treat unresectable or recurrent BRCA-mutant, HER2-negative breast cancer in patients who have received prior chemotherapy...